Serina Therapeutics financials
$2.08+3.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $130.0K | $0.00 | — | $14.0K | $51.0K | $5.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $130.0K | $0.00 | — | $14.0K | $51.0K | $5.0K |
| Gross margin | — | — | — | — | 100.0% | — | — | 100.0% | 100.0% | 100.0% |
| Operating income | -$6.8M | -$6.3M | -$6.2M | -$6.4M | -$5.6M | -$5.9M | — | -$5.3M | -$3.9M | -$2.3M |
| Net income | -$8.9M | -$6.9M | -$3.6M | -$4.6M | -$6.6M | -$4.8M | — | $1.4M | $5.2M | -$15.0M |
| Net margin | — | — | — | — | −5050.0% | — | — | 10071.4% | 10203.9% | −300300.0% |
| Diluted EPS | $-0.55 | $-0.58 | $-0.34 | $-0.45 | $-0.66 | $-0.49 | — | $0.13 | $0.51 | $-5.38 |
| EBITDA | -$6.8M | -$6.3M | -$6.2M | -$6.4M | -$5.5M | -$5.8M | $56.0K | -$5.3M | -$3.8M | -$2.3M |
| Operating cash flow | -$6.7M | -$4.6M | -$6.0M | -$3.9M | -$3.8M | -$4.3M | -$4.6M | -$3.0M | -$8.0M | -$1.6M |
| Free cash flow | -$6.7M | -$4.6M | -$6.0M | -$3.9M | -$3.8M | -$4.3M | -$4.6M | -$3.0M | -$8.0M | -$1.6M |
| Diluted shares | 16.4M | 12.0M | 10.7M | 10.3M | 10.0M | 9.8M | 5.7M | 10.8M | 10.2M | 2.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $23.0M | $24.5M | $3.1M | $8.6M | $6.0M | $4.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $3.1M | $3.0M | $2.9M | $2.9M | $0.00 | $0.00 |
| Total assets | $25.8M | $27.3M | $7.0M | $12.4M | $8.9M | $6.7M |
| Total liabilities | $7.1M | $9.7M | $7.0M | $10.8M | $7.3M | $5.2M |
| Shareholders' equity | $18.7M | $17.6M | -$37.0K | $1.6M | $1.6M | $1.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology